Health 2.0 Europe 2011

27 - 28 October 2011, Berlin, Germany.
Following the success of the first edition in Paris in April 2010, the 2nd annual Health 2.0 Europe in Berlin has been announced. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offerings with some American input too. Co-hosted with K.I.T. Group, the 2nd edition will reconvene all the leaders and stakeholders in web 2.0 health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

2011 Program Highlights
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. Health 2.0 Europe will be seeing what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in the lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions. 2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion and wellness 2.0
  • Behavior change tools
  • Privacy, data, trust
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Mobile devices and smart phones

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Make it your event. Get involved now!
To submit a topic, a speaker, or a start up for the Launch! session, or to inquire about becoming a partner of the event, please contact:

Pascal Lardier, Director, International conferences
This email address is being protected from spambots. You need JavaScript enabled to view it.

Historical Venue
After the Cité Internationale in April 2010, the 2011 event is taking us to yet another historical landmark: the Langenbeck-Virchow building of the Charité Hospital and University of Medicine.

It was built in 1914-15 to be the seat of the German Surgical Society and the Berlin Medical Association. From 1950 to 1976, the Parliament of East Germany was constituted in its auditorium and started convening in the Great Hall. After the collapse of Berlin Wall in 1989 and a long legal conflict, the German Surgical Society and the Berlin Medical Association returned to their home.

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...